Lexaria Bioscience Corp (LEXX)

$1.00 0.00 (N/A)
Market Cap 17.56M
Revenue (ttm) 460,000.00
Net Income (ttm) -5.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,260.87%
Debt to Equity Ratio 0.00
Volume 58,400
Avg Vol 110,822
Day's Range N/A - N/A
Shares Out 17.56M
Stochastic %K 40%
Beta 0.84
Analysts Strong Sell
Price Target $7.00

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH i...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Maxedout2025
Maxedout2025 Jun. 20 at 11:09 AM
$LEXX Bio Convention with the results in and the continued positive data……I would think deals are being made lets see what today and Monday bring….. this is going to get exciting!
0 · Reply
Maxedout2025
Maxedout2025 Jun. 18 at 1:11 PM
$LEXX Here we go……
0 · Reply
LongLEXX
LongLEXX Jun. 17 at 4:05 PM
$LEXX C'mon LEXX Go!!!!
0 · Reply
LongLEXX
LongLEXX Jun. 17 at 3:26 PM
$LEXX and God said...let there be LEXX and there was LEXX!
0 · Reply
Shubeedoo
Shubeedoo Jun. 17 at 1:32 PM
$LEXX Had to grab a few on the open. Either a 5 to 10 bagger or a total waste of time and money. Betting on another bump, no matter what
0 · Reply
Shubeedoo
Shubeedoo Jun. 17 at 1:31 PM
$LEXX Had to grab a few on the open. Either a 5 to 10 bagger or a waste of time and money. Betting we have another bump in the near future
0 · Reply
Maxedout2025
Maxedout2025 Jun. 17 at 12:50 PM
$LEXX
0 · Reply
Maxedout2025
Maxedout2025 Jun. 17 at 11:41 AM
$LEXX https://finance.yahoo.com/news/lexx-glp-1-h25-5-103600233.html
0 · Reply
Maxedout2025
Maxedout2025 Jun. 16 at 3:24 PM
$LEXX Completed just in time https://www.smartkarma.com/insights/lexx-glp-1-h25-5-study-complete?utm_medium=feed&utm_source=RSS
0 · Reply
Maxedout2025
Maxedout2025 Jun. 16 at 2:47 PM
$LEXX This is going to be a sight to see…… Start your engines $NVO $LLY $PFE $MRK check this out
0 · Reply
Latest News on LEXX
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 8 days ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 14 days ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 5 weeks ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 7 weeks ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 7 weeks ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 2 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 2 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 2 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 3 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 3 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 4 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 4 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 4 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 4 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 4 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Releases Annual Letter from the CEO

Jan 30, 2025, 9:15 AM EST - 5 months ago

Lexaria Releases Annual Letter from the CEO

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 5 months ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 5 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 6 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 6 months ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 6 months ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 6 months ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 7 months ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 7 months ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 7 months ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 7 months ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 7 months ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 8 months ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 8 months ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 8 months ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 8 months ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 8 months ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 9 months ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

Oct 8, 2024, 9:20 AM EDT - 9 months ago

Lexaria Updates Current GLP-1 Market

Lexaria Appoints Michael Shankman as Chief Financial Officer

Oct 1, 2024, 9:25 AM EDT - 9 months ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Sep 27, 2024, 9:20 AM EDT - 9 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Releases Strategic Letter from the Outgoing CEO

Sep 5, 2024, 10:00 AM EDT - 10 months ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO

Sep 5, 2024, 9:00 AM EDT - 10 months ago

Lexaria Welcomes Industry Veteran as New CEO

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

Sep 3, 2024, 8:30 AM EDT - 10 months ago

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

Aug 29, 2024, 9:25 AM EDT - 10 months ago

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Aug 27, 2024, 9:20 AM EDT - 10 months ago

First Results from Lexaria's Second GLP-1 Human Pilot Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Aug 22, 2024, 9:20 AM EDT - 10 months ago

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Aug 21, 2024, 9:00 AM EDT - 10 months ago

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study

Aug 19, 2024, 9:05 AM EDT - 10 months ago

Positive Results from Lexaria's Molecular Characterization Study

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Jul 17, 2024, 10:30 AM EDT - 1 year ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Lexaria Preparing For Strategic Growth

Jul 16, 2024, 9:20 AM EDT - 1 year ago

Lexaria Preparing For Strategic Growth

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

Jul 8, 2024, 9:10 AM EDT - 1 year ago

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Jun 5, 2024, 9:00 AM EDT - 1 year ago

Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Maxedout2025
Maxedout2025 Jun. 20 at 11:09 AM
$LEXX Bio Convention with the results in and the continued positive data……I would think deals are being made lets see what today and Monday bring….. this is going to get exciting!
0 · Reply
Maxedout2025
Maxedout2025 Jun. 18 at 1:11 PM
$LEXX Here we go……
0 · Reply
LongLEXX
LongLEXX Jun. 17 at 4:05 PM
$LEXX C'mon LEXX Go!!!!
0 · Reply
LongLEXX
LongLEXX Jun. 17 at 3:26 PM
$LEXX and God said...let there be LEXX and there was LEXX!
0 · Reply
Shubeedoo
Shubeedoo Jun. 17 at 1:32 PM
$LEXX Had to grab a few on the open. Either a 5 to 10 bagger or a total waste of time and money. Betting on another bump, no matter what
0 · Reply
Shubeedoo
Shubeedoo Jun. 17 at 1:31 PM
$LEXX Had to grab a few on the open. Either a 5 to 10 bagger or a waste of time and money. Betting we have another bump in the near future
0 · Reply
Maxedout2025
Maxedout2025 Jun. 17 at 12:50 PM
$LEXX
0 · Reply
Maxedout2025
Maxedout2025 Jun. 17 at 11:41 AM
$LEXX https://finance.yahoo.com/news/lexx-glp-1-h25-5-103600233.html
0 · Reply
Maxedout2025
Maxedout2025 Jun. 16 at 3:24 PM
$LEXX Completed just in time https://www.smartkarma.com/insights/lexx-glp-1-h25-5-study-complete?utm_medium=feed&utm_source=RSS
0 · Reply
Maxedout2025
Maxedout2025 Jun. 16 at 2:47 PM
$LEXX This is going to be a sight to see…… Start your engines $NVO $LLY $PFE $MRK check this out
0 · Reply
Shubeedoo
Shubeedoo Jun. 16 at 2:42 PM
$LEXX if I am the big powerful MTA partner, I would only do an all inclusive, with the anticipation of taking the company over, if the news is good. If the news is bad and we have no MTA deal, not a good place to be and we are probably done
1 · Reply
ZacksSCR
ZacksSCR Jun. 16 at 2:37 PM
$LEXX: GLP-1-H25-5 Study Complete https://buff.ly/tzaPRBG
0 · Reply
LongLEXX
LongLEXX Jun. 16 at 2:03 PM
$LEXX Seems it would be very foolish of LEXX to make an all inclusive MTA deal with anyone so probably they haven't!
0 · Reply
LongLEXX
LongLEXX Jun. 16 at 1:57 PM
$LEXX LEXX has only given a temporary exclusive license option to the MTA partner for specific concepts and formulations. For instance if we are working with Eli Lilly to investigate Tirzepatide, we could still make a deal with Novo Nordisk to investigate Semaglutide or with Sun Pharma to investigate Liraglutide. This is from the original NR LEXX put out re: the MTA. " Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination".
2 · Reply
Shubeedoo
Shubeedoo Jun. 16 at 1:21 PM
$LEXX traveler, not sure what they can do with anybody, as long as they have an exclusive MTA partner, that we have no idea who it is. Someone please correct me if I am wrong about the exclusive relationship.
0 · Reply
Maxedout2025
Maxedout2025 Jun. 16 at 1:20 PM
$LEXX Bio Convention Starts Today……….. This could be $LEXX Birthday Week HERE WE GO
0 · Reply
Traveller22
Traveller22 Jun. 16 at 11:21 AM
$LEXX hopefully there are some meaningful connections made at this weeks conference that result in collaboration or partnerships. It will be an exciting few months ahead if they do.
0 · Reply
FullportFox
FullportFox Jun. 15 at 6:27 PM
$LEXX GLP 1 is still hot
0 · Reply
LongLEXX
LongLEXX Jun. 13 at 3:43 PM
$LEXX
0 · Reply
Shubeedoo
Shubeedoo Jun. 13 at 3:21 PM
$LEXX No question Taco
0 · Reply
Maxedout2025
Maxedout2025 Jun. 13 at 3:08 PM
$LEXX
0 · Reply
Taco_stocks
Taco_stocks Jun. 13 at 2:12 PM
$LEXX The way I see it, Lexx is clearly a company that is trying to get a partner or get bought out. They have 7 employees, only one of whom is a researcher: https://www.linkedin.com/company/lexaria-bioscience/people/ The others are legal, HR and business people. This tells me their end goal isn't to bring any drugs to market themselves, but to get partnered with or bought out by a company who will, which is why the MTA is an absolute must for this stock.
2 · Reply